Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–1 of 1 stories
A Phase I study evaluates the combination of gemcitabine and cisplatin with ivosidenib or pemigatinib for advanced cholangiocarcinoma. The open-label trial aims to assess safety and efficacy in this challenging cancer type.
Read full storyGet the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.